Compare Revvity Inc (RVTY) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Wells Fargo & Co — how do they compare? Revvity Inc trades at $115.88 (market cap $12.91B), while Wells Fargo & Co trades at $88.54 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 20.5× Revvity Inc's market cap, and Wells Fargo & Co pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| RVTY | WFC | |
|---|---|---|
Market Cap | $12.91B | $264.66B |
Sector | Technology | Financials |
52-Week High | $117.75 | $96.40 |
52-Week Low | $82.26 | $73.42 |
Enterprise Value | $15.23B | — |
Dividend Yield | 0.24% | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Wells Fargo (WFC) trades at $88.53, up 1.12% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $1.96, beating expectations, and maintains strong profitability with a net income margin of 25.97% and ROE of 13.13%. Recent news highlights the launch of tokenized deposits for corporate clients and a dividend increase to $0.50 per share, reflecting strategic innovation and shareholder returns.
The outlook for WFC is positive, supported by earnings beats, digital banking initiatives, and analyst consensus leaning toward buy. Risks include volatile cash flows, with 2025 operating cash flow negative $19.0B, and competitive pressures in the banking sector. The stock offers value with a P/E of 12.72, below industry averages, but investors should monitor execution on growth strategies and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
